Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03767257 · ClinicalTrials.gov registry record · Phase 2
A Study of Colesevelam for Lenalidomide-Associated Diarrhea
A Phase 2 study of Multiple Myeloma and Diarrhea, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 7
- Study locations
NCT03767257 is a Phase 2 study of Multiple Myeloma and Diarrhea that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT03767257, a Phase 2 study of Multiple Myeloma and Diarrhea, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the safety of colesevelam and find out what effects, if any, colesevelam has on lenalidomide associated diarrhea in participants with multiple myeloma on lenalidomide maintenance.
Conditions Studied
Interventions
- DRUG Colesevelam Pill
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2024-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03767257
The ClinicalTrials.gov registry entry for NCT03767257 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Colesevelam Pill is the first listed.
NCT03767257 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03767257 about?
NCT03767257 is a clinical study titled "A Study of Colesevelam for Lenalidomide-Associated Diarrhea". The purpose of this study is to test the safety of colesevelam and find out what effects, if any, colesevelam has on lenalidomide associated diarrhea in participants with multiple myeloma on lenalidomide maintenance.
What is the current status of trial NCT03767257?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2018-12-03. Estimated completion is 2024-11-27.
What conditions does trial NCT03767257 study?
This clinical trial studies the following conditions: Multiple Myeloma, Diarrhea.
What interventions are being tested in trial NCT03767257?
The interventions under investigation include: Colesevelam Pill (DRUG).
Who is sponsoring clinical trial NCT03767257?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03767257 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.